Clinical Trials · NCT02795858
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Dana-Farber Cancer Institute
- Enrollment
- 43
- Start date
- Jun 2016
- Locations
- 2 sites, United States
- Primary endpoint
- Progression-Free Survival (PFS)